IBM Scores Analyst Upgrades and White House Quantum Backing, but Consulting Weakness Clouds the Outlook

IBM’s stock has become a study in contradictions. At €233.55, it sits 20% below its 52-week high yet 28% above its low, trapped between a fading quantum premium and a resurgent software franchise. Two analyst upgrades and fresh executive orders from Washington have given the shares a lift, but a profit warning from rival Accenture has rekindled fears about the legacy consulting arm.

JPMorgan raised its rating on the stock to Overweight, lifting the price target to $291. Analyst Brian Essex points to a fundamental shift in IBM’s profit mix: software now accounts for nearly half of revenue but roughly two-thirds of total profit. That margin-rich pivot makes the company look less like a traditional IT services firm and more like a high-margin platform business. Morgan Stanley followed suit, bumping its target to $267, with analysts citing the recurring revenue stream from cloud platform OpenShift—now $2 billion annually—and the pending HashiCorp acquisition as catalysts for a higher valuation.

The political tailwinds are equally significant. President Donald Trump signed two executive orders this week aimed at accelerating American quantum research, with a goal of fielding advanced quantum capabilities by 2028 and requiring federal agencies to shift to post-quantum cryptography by 2031. IBM is a direct beneficiary: the Commerce Department is planning $1 billion in CHIPS Act funding for a new IBM chip fabrication plant, the Anderon quantum foundry announced in May 2026. That facility, the first dedicated quantum chip factory in the U.S., will see IBM match the government’s contribution with $1 billion of its own cash, plus patents and personnel. The administration’s commitment—the largest single quantum research pledge in U.S. history, with over $2 billion flowing to nine companies—gives IBM’s multi-billion-dollar quantum development budget a solid government anchor.

Yet the market’s earlier enthusiasm for the quantum story has largely evaporated. When the Anderon news broke, IBM shares surged nearly 30% in their best monthly performance in almost 24 years, and the price-to-earnings ratio swelled to 26.5—well above the historical average of 20. Analysts estimate that roughly $82 of the stock price at the peak was pure quantum fantasy. That premium has now collapsed, refocusing attention on the core business. In the first quarter, software revenue grew 11% year-on-year to $7.1 billion, while the lower-margin consulting segment accounted for less than a third of total sales. The company has also locked in financial flexibility by extending two credit lines, keeping $10 billion in emergency liquidity available.

Should investors sell immediately? Or is it worth buying IBM?

Technically, the stock is in no man’s land. It trades just below the 200-day moving average of €235.74 and above the 50-day average of €217.09, with a relative strength index of 52.6—neutral. The consensus analyst target stands at $255.40, implying roughly 10% upside.

The biggest near-term risk comes from consulting. Accenture’s mid-June profit warning flagged weak IT consulting demand, a problem that directly threatens IBM’s own advisory business. That concern could hang over the second-quarter results due July 22. Meanwhile, IBM continues to make genuine scientific strides—a collaboration with the Cleveland Clinic and RIKEN simulated protein complexes with over 12,000 atoms using a hybrid quantum-classical system, and the company expects to demonstrate a true quantum advantage in 2026.

Investors are left weighing a short-term headwind from consulting against long-term policy support and a high-margin software engine that funds the quantum research without requiring immediate payback. The question, as ever, is whether the market will reward the vision before the qubits are ready.